Rhythm Pharmaceuticals Q3 net loss narrows 22% year over year to $41.37 million

Bitget2026/11/03 12:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Rhythm Pharmaceuticals’ third-quarter 2026 net loss attributable to common stockholders narrowed 22% year over year to $42.35 million.
Net product revenue climbed 80% year over year to $92.13 million, rising 29% from the previous quarter.
IMCIVREE received more than 700 patient start forms for acquired hypothalamic obesity through September 30, following U.S. approval in March.
A five-year term loan facility secured November 2 provides access to up to $750 million.
Commercial launch of IMCIVREE in Japan is underway, while a pivotal bivamelagon trial in acquired hypothalamic obesity is planned by year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030700PRIMZONEFULLFEED9868750) on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Rhythm Pharmaceuticals Q3 net loss narrows 22% year over year to $41.37 million

You may also like

Crypto prices